Bayer application for nifurtimox to treat pediatric patients with Chagas disease submitted for approval in US

New formulation for weight-adjusted treatment of pediatric Chagas patients age 0-18 targets most vulnerable patient group / Submission based on results of CHICO (CHagas disease In Children treated with NifurtimOx) phase III clinical study of nifurtimox in pediatric patients with Chagas disease as well as pre-clinical data / Fight against Neglected Tropical Diseases part of Bayer’s Sustainability Strategy
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news